Nothing Special   »   [go: up one dir, main page]

Reischies et al., 2000 - Google Patents

Prediction of deterioration in mild cognitive disorder in old age—neuropsychological and neurochemical parameters of dementia diseases

Reischies et al., 2000

View PDF
Document ID
11565095564935266599
Author
Reischies F
Hellweg R
Publication year
Publication venue
Comprehensive Psychiatry

External Links

Snippet

In normal senescence, an age-related impairment of cognitive function is observed. The difficult clinical question is in which cases of mild cognitive impairment (MCI) will there be a rapid cognitive decline to a dementia syndrome. Two ways to improve prognosis are …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—G01N2333/4701
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids

Similar Documents

Publication Publication Date Title
Ashton et al. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Zetterberg et al. Fluid biomarkers for mild traumatic brain injury and related conditions
Martinez-Valbuena et al. Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy
Hughes et al. Brain cholesterol metabolism, oxysterols, and dementia
Jellinger et al. Multiple system atrophy: pathogenic mechanisms and biomarkers
Frank et al. Biological markers for therapeutic trials in Alzheimer’s disease: proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease
Blennow et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
McShane et al. Anosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology
Hampel et al. Advances in the development of biomarkers for Alzheimer’s disease: from CSF total tau and Aβ1–42 proteins to phosphorylated tau protein
Armstrong et al. Spatial patterns of the tau pathology in progressive supranuclear palsy
Stefani et al. AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis
Tarnaris et al. Biomarkers in chronic adult hydrocephalus
Reischies et al. Prediction of deterioration in mild cognitive disorder in old age—neuropsychological and neurochemical parameters of dementia diseases
Baskota et al. Spectrum of tau pathologies in Huntington’s disease
Aarsland et al. Early discriminatory diagnosis of dementia with Lewy bodies: The emerging role of CSF and imaging biomarkers
Perani et al. PET neuroimaging in dementia conditions
Zetterberg et al. Chronic traumatic encephalopathy: fluid biomarkers
Cutler et al. Cerebrospinal fluid neuron-specific enolase is reduced in Alzheimer's disease
Chimthanawala et al. Non-invasive biomarkers for early detection of Alzheimer’s disease: a new-age perspective
Zhou et al. Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Alexopoulos et al. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature
Ince Dementia with Lewy bodies and Parkinson's disease dementia
CA2731247A1 (en) Csf biomarkers for the prediction of cognitive decline in alzheimer's disease patients
Chollet et al. Functional Imaging for neurodegenerative diseases
Yoshida et al. Macroscopic diagnostic clue for parkinsonism